Cargando…

Discovery of a Hydroxylamine-Based Brain-Penetrant EGFR Inhibitor for Metastatic Non-Small-Cell Lung Cancer

[Image: see text] Metastases to the brain remain a significant problem in lung cancer, as treatment by most small-molecule targeted therapies is severely limited by efflux transporters at the blood–brain barrier (BBB). Here, we report the discovery of a selective, orally bioavailable, epidermal grow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hill, Jarvis, Jones, Robert M., Crich, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683025/ https://www.ncbi.nlm.nih.gov/pubmed/37934858 http://dx.doi.org/10.1021/acs.jmedchem.3c01669

Ejemplares similares

Recent Advances in the Synthesis of Di- and Trisubstituted Hydroxylamines
por: Hill, Jarvis, et al.
Publicado: (2023)

Photolytic mechanisms of hydroxylamine
por: Thisuwan, Jittima, et al.
Publicado: (2020)

Plant cells oxidize hydroxylamines to NO
por: Rümer, Stefan, et al.
Publicado: (2009)

Downregulation of EGFR in a metastatic brain lesion of EGFR-mutated non-small cell lung cancer using a tyrosine kinase inhibitor: A case report
por: Takagaki, Masatoshi, et al.
Publicado: (2017)

BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR(T790M) mutation
por: Yin, Weimin, et al.
Publicado: (2020)

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

Identification and characterization of a novel hydroxylamine oxidase, DnfA, that catalyzes the oxidation of hydroxylamine to N(2)
por: Wu, Meng-Ru, et al.
Publicado: (2022)

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
por: Chelabi, Samy, et al.
Publicado: (2021)

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
por: Lu, Yunyun, et al.
Publicado: (2016)

Antioxidant properties of MitoTEMPOL and its hydroxylamine
por: Trnka, Jan, et al.
Publicado: (2008)

Copper-catalyzed diamination of unactivated alkenes with hydroxylamines
por: Shen, Kun, et al.
Publicado: (2015)

Cyclic Hydroxylamines as Monitors of Peroxynitrite and Superoxide-Revisited
por: Samuni, Uri, et al.
Publicado: (2021)

Kinetic resolution of indolines by asymmetric hydroxylamine formation
por: Wang, Gang, et al.
Publicado: (2021)

Quantification of EGFR mutations in primary and metastatic tumors in non-small cell lung cancer
por: Wei, Bing, et al.
Publicado: (2014)

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
por: Park, Silvia, et al.
Publicado: (2015)

First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Tatineni, Vineeth, et al.
Publicado: (2023)

Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer
por: Russo, Alessandro, et al.
Publicado: (2017)

Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
por: Berardi, Rossana, et al.
Publicado: (2013)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer
por: Bozorgmehr, Farastuk, et al.
Publicado: (2021)

Expression and Hydroxylamine Cleavage of Thymosin Alpha 1 Concatemer
por: Zhou, Liang, et al.
Publicado: (2008)

Hydroxylamine Analogue of Agmatine: Magic Bullet for Arginine Decarboxylase
por: Hyvönen, Mervi T., et al.
Publicado: (2020)

Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer
por: Abdelsalam, Esraa A., et al.
Publicado: (2022)

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
por: Bai, Hao, et al.
Publicado: (2017)

Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI
por: Yang, Beisheng, et al.
Publicado: (2021)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
por: Wang, Jun, et al.
Publicado: (2016)

Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer
por: Chicas-Sett, Rodolfo, et al.
Publicado: (2023)

Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities
por: Zubair, Tanzida, et al.
Publicado: (2023)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
por: Park, Keunchil, et al.
Publicado: (2021)

Crystal structure of N-(quinolin-6-yl)hydroxylamine
por: Rajapakse, Anuruddha, et al.
Publicado: (2014)

Hydroxylamine Derivatives as a New Paradigm in the Search of Antibacterial Agents
por: Miret-Casals, Laia, et al.
Publicado: (2018)

Photo-Induced Reactions between Glyoxal and Hydroxylamine in Cryogenic Matrices
por: Golec, Barbara, et al.
Publicado: (2022)

Catalytic Reduction of Oximes to Hydroxylamines: Current Methods, Challenges and Opportunities
por: Mas‐Roselló, Josep, et al.
Publicado: (2021)

Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei
por: Cleghorn, Laura A. T., et al.
Publicado: (2015)

Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
por: Bhandari, Shruti, et al.
Publicado: (2021)

An Aminative Rearrangement of O‐(Arenesulfonyl)hydroxylamines: Facile Access to ortho‐Sulfonyl Anilines
por: Morrill, Charlotte, et al.
Publicado: (2022)

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
por: Su, Po-Lan, et al.
Publicado: (2018)

Discovery of an OTUD3 inhibitor for the treatment of non-small cell lung cancer
por: Zhang, Yonghui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_afcqcqpu8f1dcfjn2mdgsj5aj8